Literature DB >> 3181395

Mafosfamide (ASTA-Z-7654) in vitro treatment of bone marrow does not eradicate Philadelphia-positive cells in chronic myeloid leukaemia.

B T Mortensen1, P Ernst, P Philip.   

Abstract

Bone marrow from 9 patients with Ph1+CML was treated in vitro with varying concentrations of Mafosfamide in order to test the hypothesis that selective pharmacological killing of Ph1-positive cells in CML is feasible. A marked difference in sensitivity to Mafosfamide of CFU-GM was observed, but at all concentrations 100% persistence of Ph1+ cells was noticed. We conclude that, in classical cases of Ph1-positive CML, Mafosfamide purging of bone marrow will not be effective.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3181395     DOI： 10.1111/j.1600-0609.1988.tb01184.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN： 0902-4441            Impact factor:   2.997


  2 in total

1.  Highly efficient elimination of Philadelphia leukemic cells by exposure to bcr/abl antisense oligodeoxynucleotides combined with mafosfamide.

Authors:  T Skorski; M Nieborowska-Skorska; C Barletta; L Malaguarnera; C Szcyzlik; S T Chen; B Lange; B Calabretta
Journal:  J Clin Invest       Date:  1993-07       Impact factor: 14.808

Review 2.  Benign hematopoietic progenitors in chronic myeloid leukemia: current status and future prospects.

Authors:  F Cervantes; C Rozman
Journal:  Ann Hematol       Date:  1994-09       Impact factor: 3.673
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.